TY - JOUR
T1 - Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas
T2 - Correlation of protein expression with lymph node metastases and advanced clinical stage
AU - Fracchiolla, Nicola S.
AU - Pruneri, Giancarlo
AU - Pignataro, Lorenzo
AU - Carboni, Nadia
AU - Capaccio, Pasquale
AU - Boletini, Alketa
AU - Buffa, Roberto
AU - Neri, Antonino
PY - 1997/3/15
Y1 - 1997/3/15
N2 - BACKGROUND. The molecular pathogenesis of laryngeal squamous cell carcinomas (LSCCs) is still only partially understood, although genetic alterations affecting various protooncogenes or tumor suppressor genes have often been detected. METHODS. To improve their understanding of the role of cyclin D1 in the pathogenesis of LSCCs, the authors investigated the expression of cyclin D1 protein and the amplification status of the bcl- 1/cyclin D1 locus in a panel of 58 pathologic samples. RESULTS. Expression of cyclin D1 protein was detected in 23 of the 58 patients (≃39%), 14 of whom had lymph node metastases (≃61%); of the remaining 35 patients without any detectable cyclin D1 expression, 7 had lymph node metastases (20%). Expression of cyclin D1 was detectable in 5% of the specimens of normal mucosa, 13% of those wild mild-to-moderate dysplasia, and 25% of those with severe dysplasia. Amplification of the bcl-1/cyclin D1 locus was detected in 12 of the 49 LSCCs investigated (≃24%), 7 of which had lymph node metastases (≃58%); of the remaining 37 LSCCs with an apparently normal copy number of the cyclin D1 locus, 12 had lymph node metastases (≃32%). The authors found almost complete concordance between locus amplification and protein expression. Statistical analysis showed a correlation between cyclin D1 expression and both the presence of lymph node metastases (P <0.01) and advanced clinical stage (P <0.02). CONCLUSIONS. The authors' observations suggest that the deregulation of cyclin D1 expression may be involved in the pathogenesis of more aggressive LSCCs.
AB - BACKGROUND. The molecular pathogenesis of laryngeal squamous cell carcinomas (LSCCs) is still only partially understood, although genetic alterations affecting various protooncogenes or tumor suppressor genes have often been detected. METHODS. To improve their understanding of the role of cyclin D1 in the pathogenesis of LSCCs, the authors investigated the expression of cyclin D1 protein and the amplification status of the bcl- 1/cyclin D1 locus in a panel of 58 pathologic samples. RESULTS. Expression of cyclin D1 protein was detected in 23 of the 58 patients (≃39%), 14 of whom had lymph node metastases (≃61%); of the remaining 35 patients without any detectable cyclin D1 expression, 7 had lymph node metastases (20%). Expression of cyclin D1 was detectable in 5% of the specimens of normal mucosa, 13% of those wild mild-to-moderate dysplasia, and 25% of those with severe dysplasia. Amplification of the bcl-1/cyclin D1 locus was detected in 12 of the 49 LSCCs investigated (≃24%), 7 of which had lymph node metastases (≃58%); of the remaining 37 LSCCs with an apparently normal copy number of the cyclin D1 locus, 12 had lymph node metastases (≃32%). The authors found almost complete concordance between locus amplification and protein expression. Statistical analysis showed a correlation between cyclin D1 expression and both the presence of lymph node metastases (P <0.01) and advanced clinical stage (P <0.02). CONCLUSIONS. The authors' observations suggest that the deregulation of cyclin D1 expression may be involved in the pathogenesis of more aggressive LSCCs.
KW - cyclin D1
KW - gene amplification
KW - laryngeal squamous cell carcinoma
KW - protein expression
UR - http://www.scopus.com/inward/record.url?scp=0030942852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030942852&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0142(19970315)79:6<1114::AID-CNCR9>3.0.CO;2-F
DO - 10.1002/(SICI)1097-0142(19970315)79:6<1114::AID-CNCR9>3.0.CO;2-F
M3 - Article
C2 - 9070488
AN - SCOPUS:0030942852
VL - 79
SP - 1114
EP - 1121
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 6
ER -